Meqsel® (Trametinib) — MEK Inhibitor for BRAF V600-Mutated Cancers

The First Approved MEK Inhibitor — Transforming Outcomes in BRAF-Mutated Melanoma and Beyond

Meqsel® (Trametinib) is a selective, allosteric MEK1 and MEK2 (mitogen-activated extracellular signal-regulated kinase 1 and 2) inhibitor — used as monotherapy and in combination with Rafinlar (Dabrafenib) for the treatment of BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, non-small cell lung cancer (NSCLC), anaplastic thyroid cancer (ATC), and other BRAF V600E-mutated solid tumours. Trametinib was the first MEK inhibitor approved for any cancer indication — establishing MEK inhibition as a clinically validated approach to BRAF-driven malignancies.

MEK1 and MEK2 are critical kinases in the RAS/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signalling pathway — one of the most frequently mutated oncogenic pathways in human cancer. In tumours harbouring BRAF V600 mutations, BRAF is constitutively activated → drives continuous MEK1/2 → ERK activation → uncontrolled tumour cell proliferation and survival. Trametinib inhibits MEK1/2 — blocking this downstream signal and arresting tumour cell growth.

Crucially, Trametinib is most commonly used in combination with Rafinlar (Dabrafenib) — a BRAF inhibitor — creating dual MAPK pathway blockade that overcomes the paradoxical MAPK pathway reactivation that limits single-agent BRAF inhibitor therapy. The Dabrafenib + Trametinib combination has become one of the most important precision oncology regimens across multiple tumour types — with proven survival benefit in melanoma, NSCLC, ATC, and emerging data in other BRAF-mutated solid tumours.

A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Meqsel (Trametinib) in both 0.5mg and 2mg strengths to hospitals, oncology centres, and pharmacies across India. Manufactured by Novartis India Ltd, Meqsel is available at accessible pricing for Indian patients requiring MEK inhibitor therapy.

What is Meqsel (Trametinib)?

Meqsel contains Trametinib — a highly selective, small molecule allosteric inhibitor of MEK1 and MEK2 kinases. Trametinib binds to an allosteric site on MEK1/2 — adjacent to but distinct from the ATP-binding site — locking MEK in an inactive conformation and preventing both MEK activation by upstream BRAF and MEK-mediated phosphorylation of downstream ERK.

The MAPK Pathway and BRAF V600 Mutations:

The MAPK signalling cascade (RAS → RAF → MEK → ERK) is a fundamental cell proliferation and survival pathway activated by growth factor receptors. In normal cells this pathway is tightly regulated — activated transiently by growth factors and then switched off.

BRAF V600 mutations — most commonly V600E (valine to glutamate substitution at position 600) and V600K — create a constitutively active BRAF kinase that continuously drives MEK → ERK signalling independent of upstream RAS activation. This constitutive MAPK pathway activation:

• Drives continuous tumour cell proliferation
• Suppresses apoptosis — tumour cell survival
• Promotes tumour invasion and metastasis
• Drives resistance to many conventional therapies

BRAF V600 mutations occur in:

• Melanoma — approximately 50% of cutaneous melanomas
• NSCLC — approximately 2-4% of adenocarcinomas
• Anaplastic thyroid cancer — approximately 40-60%
• Colorectal cancer — approximately 10%
• Glioma — approximately 15-20% of paediatric gliomas
• Other solid tumours — varying frequencies across tumour types

Why Combination With Dabrafenib Is Superior to Either Agent Alone:

BRAF inhibitors (Dabrafenib) as single agents show impressive initial responses in BRAF-mutated tumours — but resistance develops rapidly (median PFS approximately 5-7 months). A key resistance mechanism is paradoxical MAPK pathway reactivation — BRAF inhibition activates RAS → RAS drives CRAF dimerisation → CRAF drives MEK → ERK reactivation independent of BRAF. Adding MEK inhibition (Trametinib) blocks this downstream reactivation — preventing paradoxical resistance, significantly extending duration of response, and improving OS compared to BRAF inhibitor monotherapy.

Full prescribing information is available at the FDA label for Trametinib.

Clinical Studies and Evidence

METRIC Trial (Trametinib vs Chemotherapy in BRAF V600-Mutated Melanoma) Published in the New England Journal of Medicine (2012), the METRIC trial was the pivotal Phase 3 randomised controlled trial of 322 patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma — comparing Trametinib monotherapy vs chemotherapy (Dacarbazine or Paclitaxel). Key results:

• Progression-free survival — median PFS 4.8 months (Trametinib) vs 1.5 months (chemotherapy) — HR 0.45 — significantly improved
• Overall survival at 6 months — 81% (Trametinib) vs 67% (chemotherapy) — significantly improved
• Objective response rate — 22% vs 8%
• Established Trametinib as the first approved MEK inhibitor — with significantly superior outcomes vs chemotherapy in BRAF V600-mutated metastatic melanoma

COMBI-d Trial (Dabrafenib + Trametinib vs Dabrafenib Monotherapy in Melanoma) Published in the New England Journal of Medicine (2014) with updated OS data in The Lancet (2016), COMBI-d compared Dabrafenib + Trametinib vs Dabrafenib alone in 423 patients with BRAF V600E/K metastatic melanoma. Key results at 5-year follow-up:

• Median PFS — 11.0 months (combination) vs 8.8 months (Dabrafenib alone) — HR 0.67 — significantly improved
• Median OS — 25.1 months (combination) vs 18.7 months (Dabrafenib alone) — HR 0.71 — significantly improved
• 5-year OS rate — 27% (combination) vs 22% (Dabrafenib alone)
• 5-year PFS rate — 19% (combination) vs 12% (Dabrafenib alone)
• Demonstrated sustained long-term benefit with 19% of patients remaining progression-free at 5 years — a remarkable result in metastatic melanoma

COMBI-v Trial (Dabrafenib + Trametinib vs Vemurafenib in Melanoma) Published in the New England Journal of Medicine (2015), COMBI-v compared Dabrafenib + Trametinib vs Vemurafenib (another BRAF inhibitor) in 704 patients with BRAF V600E/K metastatic melanoma. Key results:

• Overall survival — significantly improved with combination — median OS 25.6 months vs 18.0 months — HR 0.66
• 1-year OS — 72% vs 65%
• Established Dabrafenib + Trametinib combination as superior to BRAF inhibitor monotherapy — becoming the standard of care for BRAF V600-mutated metastatic melanoma

BRF113928 Trial (Dabrafenib + Trametinib in BRAF V600E NSCLC) Published in the New England Journal of Medicine (2017), this Phase 2 trial demonstrated:

• ORR — 64.2% in patients with BRAF V600E-mutated metastatic NSCLC receiving Dabrafenib + Trametinib
• Median PFS — 10.9 months
• Median OS — 18.2 months
• Established Dabrafenib + Trametinib as the first approved targeted therapy for BRAF V600E-mutated NSCLC — a biomarker-defined subset with no prior targeted option

BRF117019 Trial (Dabrafenib + Trametinib in Anaplastic Thyroid Cancer) Published in the Journal of Clinical Oncology (2018), this Phase 2 basket study demonstrated:

• ORR — 69% in BRAF V600E-mutated anaplastic thyroid cancer
• Complete response rate — 38%
• Median OS — 14.5 months — remarkable in ATC which historically had median survival of 3-5 months
• Established Dabrafenib + Trametinib as the first approved targeted therapy for BRAF V600E ATC — transforming a rapidly fatal disease

ROAR and NCI-MATCH Basket Trials (Dabrafenib + Trametinib in Other BRAF V600E Solid Tumours) These tumour-agnostic basket trials demonstrated Dabrafenib + Trametinib activity across multiple BRAF V600E-mutated solid tumours — leading to the first tumour-agnostic approval of this combination for any BRAF V600E-mutated solid tumour after prior therapy.

Available Strengths

Meqsel (Trametinib) is available in the following strengths:

Standard dose: 2mg orally once daily — taken consistently at the same time each day.

Storage — Critical: Meqsel tablets should be stored in a refrigerator at temperatures between 2°C to 8°C and protected from light and moisture. Do not freeze the medication. BioXconomy This is important — Trametinib requires cold chain storage — different from room temperature storage of most oral oncology tablets.

Indications — What Meqsel is Used For

Unresectable or Metastatic Melanoma:

• As monotherapy for BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma
• In combination with Rafinlar (Dabrafenib) for BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma
• Combination is preferred over monotherapy — superior efficacy and lower rates of cutaneous toxicity

BRAF V600E-Mutated NSCLC:

• In combination with Dabrafenib for metastatic NSCLC with BRAF V600E mutation — after prior platinum-based chemotherapy (or as first-line per updated indications)

Anaplastic Thyroid Cancer:

• In combination with Dabrafenib for locally advanced or metastatic ATC with BRAF V600E mutation — no satisfactory locoregional treatment option

BRAF V600E-Mutated Solid Tumours (Tumour Agnostic):

• In combination with Dabrafenib for unresectable or metastatic solid tumours with BRAF V600E mutation after prior treatment and no satisfactory alternative treatment option

Important — BRAF V600 Mutation Testing Is Mandatory: Before prescribing Meqsel (Trametinib) for any indication, BRAF V600 mutation status must be confirmed using a validated diagnostic test. BRAF wild-type patients receive no benefit and should not receive BRAF/MEK inhibitor therapy.

For detailed indication information refer to MedlinePlus Trametinib.

Key Benefits of Meqsel

First-in-Class MEK Inhibitor — Validated Precision Oncology Target Trametinib was the first MEK inhibitor approved for any cancer — establishing MEK1/2 inhibition as a clinically proven approach to BRAF-driven malignancies. The METRIC trial demonstrated superior outcomes vs chemotherapy in a randomised trial — proving single-agent MEK inhibition is clinically meaningful in BRAF-mutated melanoma.

Synergistic Combination With Dabrafenib — Dual MAPK Blockade The Dabrafenib + Trametinib combination achieves simultaneous BRAF and MEK inhibition — addressing both the primary oncogenic driver (BRAF V600) and the paradoxical reactivation resistance mechanism (CRAF-driven MEK activation). This dual blockade translates to significantly longer PFS and OS compared to BRAF inhibitor monotherapy — with 19% 5-year PFS in the COMBI-d trial representing durable long-term disease control in a significant proportion of metastatic melanoma patients.

Transformative Activity in Anaplastic Thyroid Cancer ATC historically had median survival of 3-5 months with no effective systemic therapy. Dabrafenib + Trametinib achieved 69% ORR and 14.5-month median OS in BRAF V600E ATC — representing a paradigm shift in the management of this previously rapidly fatal cancer.

Tumour-Agnostic Activity — Applicable Across Multiple BRAF V600E-Mutated Cancers The tumour-agnostic approval of Dabrafenib + Trametinib for any BRAF V600E-mutated solid tumour reflects the fundamental oncogene-driven nature of BRAF V600 signalling — the same mutation driving the same pathway in melanoma, lung cancer, thyroid cancer, colorectal cancer, and glioma all respond to the same targeted combination.

Reduced Cutaneous Toxicity vs BRAF Inhibitor Monotherapy BRAF inhibitors as monotherapy cause paradoxical ERK activation in RAS wild-type keratinocytes → cutaneous squamous cell carcinoma (cuSCC) and keratoacanthoma in 15-20% of patients. Adding Trametinib (MEK inhibitor) blocks this paradoxical ERK activation in skin → dramatically reduces cuSCC from 15-20% to <1% — an important safety benefit of the combination over BRAF inhibitor monotherapy.

Both Strengths Available — Complete Dose Management A.K. Pharma supplies both 0.5mg and 2mg Trametinib — enabling the standard 2mg dose and dose reductions to 1.5mg (three 0.5mg tablets) when required for toxicity management.

How Meqsel Works — MEK Inhibition in BRAF-Mutated Cancers

The Normal MAPK Pathway: Growth factor → receptor tyrosine kinase activation → RAS activation → RAF activation → MEK1/2 phosphorylation and activation → ERK1/2 phosphorylation and activation → ERK translocates to nucleus → transcription factors activated → proliferation genes expressed → cell cycle progression.

BRAF V600 Mutation — Constitutive Activation: BRAF V600E/K mutation → constitutively active BRAF kinase → continuously phosphorylates and activates MEK1/2 → continuous ERK activation → continuous transcription of proliferation genes → uncontrolled tumour cell growth — independent of growth factor input.

Trametinib’s Mechanism:

Step 1 — Allosteric MEK1/2 Binding: Trametinib binds to an allosteric site on MEK1 and MEK2 — adjacent to the kinase domain but distinct from the ATP-binding site. This allosteric binding locks MEK in an inactive conformation — preventing both upstream BRAF-mediated MEK activation and MEK-mediated ERK phosphorylation simultaneously.

Step 2 — ERK Phosphorylation Blockade: Without MEK1/2 activity, ERK1/2 cannot be phosphorylated → inactive ERK cannot translocate to the nucleus → ERK target transcription factors (ETS, AP-1 family) are not activated → proliferation gene expression is suppressed.

Step 3 — Cell Cycle Arrest and Apoptosis: Suppression of ERK-driven transcription leads to reduced cyclin D1 expression → CDK4/6 inhibition → Rb hypophosphorylation → G1 cell cycle arrest. Simultaneously, ERK suppression reduces anti-apoptotic BCL-2 family protein expression → increased apoptosis sensitivity.

Why Combination Dabrafenib + Trametinib is Superior:

BRAF inhibitor monotherapy initially blocks BRAF V600 → ERK → tumour response. However:

• BRAF inhibition → paradoxical RAS activation → RAS drives CRAF (not BRAF) → CRAF dimerises with BRAF → MEK activation via CRAF is independent of BRAF V600 → ERK reactivation → resistance to BRAF inhibitor
• Adding Trametinib blocks MEK activation regardless of whether it is driven by mutant BRAF V600 or wild-type CRAF → prevents paradoxical resistance mechanism → sustained MAPK pathway suppression → longer responses

For detailed mechanism overview refer to ESMO Melanoma Guidelines and NCCN Melanoma Guidelines.

Meqsel + Rafinlar — The Dabrafenib + Trametinib Combination Regimen

At A.K. Pharma both components of the Dabrafenib + Trametinib combination are available:

Standard Combination Dosing:

• Trametinib 2mg orally once daily — on an empty stomach (1 hour before or 2 hours after a meal)
• Dabrafenib 150mg orally twice daily (approximately 12 hours apart) — on an empty stomach

Tumour Types and BRAF Testing Required:

Dosage and Administration

Trametinib (Meqsel) Standard Dose:

• 2mg orally once daily — on an empty stomach
• Take at least 1 hour before or 2 hours after a meal
• Take at approximately the same time each day
• Swallow tablets whole — do not crush, chew, or split
• If a dose is missed and it is more than 12 hours until the next scheduled dose — take the missed dose. If less than 12 hours — skip the missed dose

When Used With Dabrafenib:

• Trametinib 2mg once daily (same empty stomach requirement)
• Dabrafenib 150mg twice daily (12 hours apart) — also on empty stomach
• Both medicines have empty stomach requirements — coordinate timing accordingly

Dose Reduction for Toxicity:

• First reduction: 1.5mg once daily (three 0.5mg tablets)
• Second reduction: 1.0mg once daily (two 0.5mg tablets)
• If 1.0mg once daily not tolerated — permanently discontinue

Important Storage Reminder: Trametinib tablets must be stored in a refrigerator between 2°C and 8°C — take out of refrigerator just before administration. Do not leave at room temperature for extended periods.

Monitoring:

• Echocardiogram/LVEF — at baseline, 1 month after starting, then every 2-3 months
• Dermatological assessment — for rash, cuSCC (less common than with BRAF monotherapy), hand-foot skin reaction
• Ophthalmological assessment — for blurred vision, visual changes (Retinal Pigment Epithelial Detachment — RPED risk)
• Blood pressure — monitor regularly — hypertension is common
• LFTs — monitor periodically
• Blood glucose — monitor particularly in diabetic patients
• Signs of haemorrhage — monitor throughout

Full dosing guidelines available at Drugs.com Trametinib Dosage.

BRAF V600 Mutation Testing — Essential Before Prescribing

Meqsel (Trametinib) must only be used in patients with confirmed BRAF V600 mutation. Testing options:

• Tissue-based PCR or NGS — from tumour biopsy (primary or metastatic site) — gold standard
• Liquid biopsy (ctDNA) — circulating tumour DNA testing — non-invasive but may have lower sensitivity
• IHC — immunohistochemistry for BRAF V600E — available but less specific than molecular testing

CDSCO-approved BRAF V600 testing is available at major cancer centres across India. Re-biopsy of metastatic lesions may be required if the primary tumour biopsy tested negative — tumour heterogeneity and clonal evolution can result in BRAF V600 mutations being present in metastatic deposits but absent in the primary.

Who Should Use Meqsel

Meqsel (Trametinib) is prescribed for:

Melanoma:

• Adults with BRAF V600E or V600K mutation-positive unresectable or metastatic cutaneous melanoma
• Confirmed BRAF V600 mutation by validated test is mandatory
• Dabrafenib + Trametinib combination preferred over Trametinib monotherapy — superior efficacy
• Not for BRAF wild-type melanoma

NSCLC:

• Adults with BRAF V600E mutation-positive metastatic NSCLC — adenocarcinoma histology most common
• In combination with Dabrafenib
• BRAF V600E mutation testing by NGS recommended — typically co-tested with EGFR, ALK, ROS1, KRAS, MET

Anaplastic Thyroid Cancer:

• Adults with locally advanced or metastatic BRAF V600E mutation-positive ATC
• In combination with Dabrafenib
• Rapid disease progression in ATC requires prompt BRAF testing and treatment initiation

Other BRAF V600E-Mutated Solid Tumours:

• Adults with unresectable or metastatic BRAF V600E-mutated solid tumours after prior therapy
• In combination with Dabrafenib
• Per treating oncologist’s assessment of benefit-risk

Meqsel is prescribed by medical oncologists, dermatologists (for melanoma), thoracic oncologists, and endocrinologists/thyroid cancer specialists. A.K. Pharma supplies Meqsel to hospitals, oncology centres, and pharmacies across Delhi and India.

Possible Side Effects

Common side effects of Trametinib monotherapy include rash (57%), diarrhoea (43%), lymphoedema (32%), acneiform dermatitis (19%), peripheral oedema (26%), fatigue (26%), and nausea (26%).

When used in combination with Dabrafenib — side effect profile changes — some Trametinib-specific toxicities (rash) are reduced while Dabrafenib-specific toxicities (fever, fatigue, arthralgias) are added. The combination’s overall tolerability is generally better than expected from combining two targeted therapies.

Serious side effects include:

Cardiomyopathy/Decreased LVEF: Trametinib can cause cardiomyopathy and decreased LVEF — occurring in approximately 7-11% of patients. Monitor LVEF at baseline, 1 month, and every 2-3 months. Withhold for asymptomatic decrease ≥10% from baseline and to below institutional lower limit of normal. Permanently discontinue for symptomatic CHF or persistent LVEF decrease.

Retinal Pigment Epithelial Detachment (RPED): Blurred vision, visual changes, and photopsia may indicate RPED — a serious ocular complication requiring ophthalmological evaluation and treatment interruption.

Interstitial Lung Disease (ILD)/Pneumonitis: Serious ILD occurs in approximately 2% — monitor for new respiratory symptoms; withhold pending evaluation; permanently discontinue for confirmed Grade 3-4 ILD.

Serious Skin Toxicity: Erythema multiforme, Stevens-Johnson syndrome, and drug reaction with eosinophilia and systemic symptoms (DRESS) — rare but serious; permanently discontinue.

Haemorrhage: Serious haemorrhagic events including intracranial and gastrointestinal haemorrhage — permanently discontinue for life-threatening bleeding.

Venous Thromboembolism: DVT and PE — monitor throughout treatment.

Hyperglycaemia: Particularly when combined with Dabrafenib — monitor blood glucose; manage with anti-diabetic therapy as needed.

Full side effect information available at FDA Trametinib Safety Information.

Precautions

• BRAF V600 mutation testing — mandatory before prescribing; use validated diagnostic test
• Cardiac monitoring — LVEF assessment at baseline, 1 month, every 2-3 months; withhold/discontinue for significant decrease
• Ophthalmological monitoring — prompt evaluation for any visual symptoms; risk of RPED, uveitis, iritis
• ILD monitoring — monitor for new respiratory symptoms; CT evaluation if suspected
• Haemorrhage — monitor for bleeding events; withhold for significant bleeding
• Empty stomach requirement — take at least 1 hour before or 2 hours after food — food significantly affects absorption
• Cold storage — refrigerate between 2°C and 8°C — do not leave at room temperature
• Pregnancy — highly teratogenic; effective contraception required during treatment and for 4 months after last dose; pregnancy test before starting in women of reproductive potential
• Breastfeeding — discontinue during treatment and for 4 months after last dose
• CYP3A4 interactions — Trametinib is a CYP3A4 substrate; strong inhibitors increase levels; strong inducers decrease levels
• Refer to ESMO Melanoma Guidelines for complete management context

Storage and Handling

• Store in refrigerator between 2°C and 8°C — cold chain required
• Do not freeze
• Protect from light and moisture — keep in original bottle with desiccant
• Keep tightly closed
• Keep out of reach of children
• Take tablets out of refrigerator immediately before administration

As a responsible medicine distributor in Delhi, A.K. Pharma maintains full cold chain requirements during storage and supply of Meqsel ensuring product integrity for every unit supplied. Cold chain maintenance for an oral tablet is unusual — confirm cold storage arrangements with the dispensing pharmacy.

Manufacturer Information

Meqsel (Trametinib) is manufactured by Novartis India Ltd — the Indian subsidiary of Novartis AG, a global pharmaceutical leader. Trametinib received FDA approval in May 2013 as the first MEK inhibitor approved for any cancer indication — for unresectable or metastatic melanoma. A.K. Pharma supplies only genuine Meqsel sourced from authorized Novartis distributors.

Related Cancer Medicines Available at A.K. Pharma

• Rafinlar (Dabrafenib) — BRAF inhibitor — the essential combination partner for Meqsel in BRAF-mutated cancers
• Tagrisso (Osimertinib) — EGFR inhibitor for EGFR-mutant NSCLC
• Imfinzi (Durvalumab) — anti-PD-L1 checkpoint inhibitor for lung cancer
• Nitib (Nilotinib) — BCR-ABL TKI for CML
• Browse all Cancer Medicines available at A.K. Pharma

Frequently Asked Questions

Q. What is Meqsel used for? Meqsel (Trametinib) is used to treat BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma — as monotherapy or in combination with Rafinlar (Dabrafenib). It is also used in combination with Dabrafenib for BRAF V600E-mutated NSCLC, anaplastic thyroid cancer, and other BRAF V600E-mutated solid tumours. More information available at MedlinePlus.

Q. What is the generic name of Meqsel? The generic name of Meqsel is Trametinib. It is a selective MEK1/2 inhibitor — the first approved MEK inhibitor for cancer treatment — manufactured by Novartis India Ltd.

Q. Is BRAF testing required before taking Meqsel? Yes — BRAF V600 mutation testing is mandatory before prescribing Meqsel. Only patients with confirmed BRAF V600E or V600K mutations should receive Trametinib. BRAF wild-type patients receive no benefit and should not be treated. Testing is available at major cancer centres across India using PCR, NGS, or IHC methods.

Q. Why is Meqsel usually used with Rafinlar (Dabrafenib)? Trametinib monotherapy shows activity in BRAF V600-mutated melanoma but resistance develops due to paradoxical MAPK pathway reactivation through CRAF. Combining with Dabrafenib (BRAF inhibitor) blocks this resistance mechanism — providing dual MAPK pathway suppression that translates to significantly better PFS and OS. The combination also reduces Dabrafenib-associated cutaneous squamous cell carcinoma from 15-20% to <1%.

Q. Does Meqsel need to be stored in a fridge? Yes — unlike most oral cancer tablets, Trametinib requires refrigeration between 2°C and 8°C. Do not freeze. This is an important point for patients and pharmacies. A.K. Pharma maintains cold chain storage for Meqsel throughout storage and supply.

Q. What are the two strengths of Meqsel and how are they used? Meqsel 2mg is the standard dose — one 2mg tablet once daily. Meqsel 0.5mg is the dose reduction strength — used when patients require dose reduction due to toxicity (1.5mg = three 0.5mg tablets; 1.0mg = two 0.5mg tablets). A.K. Pharma supplies both strengths for complete dose management.

Q. Can Meqsel be used for lung cancer? Yes — in combination with Rafinlar (Dabrafenib) for BRAF V600E mutation-positive metastatic NSCLC. BRAF V600E mutations occur in approximately 2-4% of NSCLC adenocarcinomas. NGS-based comprehensive molecular profiling is recommended for all NSCLC patients to identify actionable mutations including BRAF V600E.

Q. Is Meqsel available in India? Meqsel (Trametinib) can be supplied to hospitals, oncology centres, and pharmacies across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for availability and pricing.

Q. What is the price of Meqsel in India? Meqsel price in India varies by strength and pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.

Q. How to order Meqsel from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.

Q. Does A.K. Pharma supply Meqsel in bulk? Yes. A.K. Pharma supplies Meqsel in bulk to oncology centres, hospitals, and pharmacies across Delhi and India with cold chain maintained throughout. Contact us for bulk pricing and availability.

Why Order Meqsel from A.K. Pharma?

• Licensed medicine distributor in Delhi with all required drug licenses
• 100% genuine Meqsel sourced from authorized Novartis distributors
• Cold chain maintained throughout storage and supply — essential for Trametinib
• Both 0.5mg and 2mg strengths available — complete dose management support
• Available alongside Rafinlar (Dabrafenib) — both components of the combination regimen in one supplier
• Bulk supply available for hospitals and oncology centres
• Prompt response to all quote requests
• Serving oncologists and cancer specialists across Delhi NCR and India

Contact A.K. Pharma for Meqsel Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in